These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 36721907)

  • 1. Pulmonary vasodilator therapies in pulmonary arterial hypertension associated with CHD: a systematic review and network meta-analysis.
    Yasuhara J; Watanabe K; Watanabe A; Shirasu T; Matsuzaki Y; Watanabe H; Takagi H; Sumitomo N; Kuno T
    Cardiol Young; 2023 Nov; 33(11):2297-2311. PubMed ID: 36721907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.
    Chen Y; Li F; Luo J; Chen J; Luo P; Li J
    Can Respir J; 2021; 2021():1626971. PubMed ID: 34512819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Long-Term Oral Bosentan in Different Types of Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis.
    Kuang HY; Li Q; Du HA; Chen M; Yin YH
    Am J Cardiovasc Drugs; 2021 Mar; 21(2):181-191. PubMed ID: 32918210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.
    McLaughlin V; Channick RN; Ghofrani HA; Lemarié JC; Naeije R; Packer M; Souza R; Tapson VF; Tolson J; Al Hiti H; Meyer G; Hoeper MM
    Eur Respir J; 2015 Aug; 46(2):405-13. PubMed ID: 26113687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
    Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
    Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
    [No Abstract]   [Full Text] [Related]  

  • 7. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of randomized controlled trials on treatment of pulmonary arterial hypertension.
    He B; Zhang F; Li X; Tang C; Lin G; Du J; Jin H
    Circ J; 2010 Jul; 74(7):1458-64. PubMed ID: 20519876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease.
    Zeng WJ; Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Gu Q; Zhao ZH; Li JJ; He JG;
    Clin Cardiol; 2011 Aug; 34(8):513-8. PubMed ID: 21678455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis.
    Kuang HY; Wu YH; Yi QJ; Tian J; Wu C; Shou WN; Lu TW
    Medicine (Baltimore); 2018 Mar; 97(10):e0075. PubMed ID: 29517668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil for adult Asian patients with pulmonary arterial hypertension: a systematic review and meta-analysis.
    Shi Q; Wang Z; Yang N; Ma Y; Chen Y; Wei H; Yao H
    Ann Palliat Med; 2022 Jan; 11(1):339-351. PubMed ID: 35144425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining bosentan and sildenafil in pulmonary arterial hypertension patients failing monotherapy: real-world insights.
    Dardi F; Manes A; Palazzini M; Bachetti C; Mazzanti G; Rinaldi A; Albini A; Gotti E; Monti E; Bacchi Reggiani ML; Galiè N
    Eur Respir J; 2015 Aug; 46(2):414-21. PubMed ID: 26022952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
    Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
    Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
    [No Abstract]   [Full Text] [Related]  

  • 14. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.
    D'Alto M; Romeo E; Argiento P; Sarubbi B; Santoro G; Grimaldi N; Correra A; Scognamiglio G; Russo MG; Calabrò R
    Int J Cardiol; 2012 Mar; 155(3):378-82. PubMed ID: 21081251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open-label, multicentre pilot study of bosentan in pulmonary arterial hypertension related to congenital heart disease.
    Ibrahim R; Granton JT; Mehta S
    Can Respir J; 2006; 13(8):415-20. PubMed ID: 17149459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
    Durongpisitkul K; Jakrapanichakul D; Sompradikul S
    J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
    Porhownik NR; Myers R; Bshouty Z
    Can Respir J; 2013; 20(2):111-5. PubMed ID: 23616968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
    Kamata Y; Iwamoto M; Minota S
    Lupus; 2007; 16(11):901-3. PubMed ID: 17971364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: a qualitative systematic review.
    Fine N; Dias B; Shoemaker G; Mehta S
    Can J Cardiol; 2009 Mar; 25(3):e63-8. PubMed ID: 19279988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.